

ASX RELEASE

Full Year Financial Results Release Date and Conference Call

Wellington, NZ, 25th May 2017: Volpara Health Technologies ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, is pleased to advise shareholders the financial results for the full year ended 31 March 2017, will be released on Monday, 29 May 2017 and a conference call will be held to update investors.

Conference call details:

Time: 11.15am (New Zealand Standard Time) / 9.15am (Australian Eastern Standard Time)

Date: Monday, 29 May 2017

Meeting number (access code): 820 938 748

Should you require a password: volpara

To access the conference call online:

1. Click link WebEx link to join meeting:
<https://signin.webex.com/collabs/#/meetings/joinbynumber>
2. Enter the meeting number (820 938 748), name and email
3. Click join call

To dial into the conference call:

Australia Toll	+61-28518-1925
Austria Toll	+43-125-302-1544
Belgium Toll	+32-2894-8321
Call-in toll number (US/Canada)	1-650-479-3208
Canada Toll	+1-416-915-9996
Czech Republic Toll	+42-0-22598-6575
Denmark Toll	+45-3272-7728
Finland Toll	+358-9315-84365
France Toll	+33-17091-8649
Germany Toll	+49-6925511-4401
Hong Kong Toll	+852-5808-1926
Hungary - Budapest Toll	+36-1700-8749
Hungary - Outside Budapest Toll	+36-1700-8750
Ireland Toll	+353-1526-0060
Italy Toll	+39-023041-0442
Japan Toll	+81-34580-8167
Luxembourg Toll	+352-2088-1754
Netherlands Toll	+31-20794-7997
New Zealand Toll	+64-9929-1751
Norway Toll	+47-2104-9768
Poland Toll	+48-2221-20697
Russia (Moscow ONLY) Toll	+7-4952-217145

Singapore Toll	+65-3158-1441
South Africa Toll	+27-11019-7061
Spain Toll	+34-91791-1287
Sweden Toll	+46-85051-3568
Switzerland Toll	+41-43456-9567
United Kingdom Toll	44-203-478-5287

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 35 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722